230 related articles for article (PubMed ID: 26373844)
21. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Sampera A; Sánchez-Martín FJ; Arpí O; Visa L; Iglesias M; Menéndez S; Gaye É; Dalmases A; Clavé S; Gelabert-Baldrich M; Poulsen TT; Kragh M; Bellosillo B; Albanell J; Rovira A; Montagut C
Mol Cancer Ther; 2019 Nov; 18(11):2135-2145. PubMed ID: 31484705
[TBL] [Abstract][Full Text] [Related]
22. The self-renewal signaling pathways utilized by gastric cancer stem cells.
Fu Y; Li H; Hao X
Tumour Biol; 2017 Apr; 39(4):1010428317697577. PubMed ID: 28378630
[TBL] [Abstract][Full Text] [Related]
23. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
[TBL] [Abstract][Full Text] [Related]
24. Upregulated miR-132 in Lgr5
Zhang L; Guo X; Zhang D; Fan Y; Qin L; Dong S; Zhang L
Mol Carcinog; 2017 Sep; 56(9):2022-2034. PubMed ID: 28383763
[TBL] [Abstract][Full Text] [Related]
25. A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells.
Yao H; Sun L; Li J; Zhou X; Li R; Shao R; Zhang Y; Li L
Int J Nanomedicine; 2020; 15():7013-7034. PubMed ID: 33061365
[TBL] [Abstract][Full Text] [Related]
26. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE
Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123
[TBL] [Abstract][Full Text] [Related]
27. DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
Qiu L; Ma Z; Li X; Deng Y; Duan G; Zhao LE; Xu X; Xiao L; Liu H; Zhu Z; Chen H
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1202-1214. PubMed ID: 33079995
[TBL] [Abstract][Full Text] [Related]
28. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
29. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.
Blay JY; Casali PG; Dei Tos AP; Le Cesne A; Reichardt P
Oncology; 2015; 89(1):1-13. PubMed ID: 25720422
[TBL] [Abstract][Full Text] [Related]
30. MGr1-Ag/37LRP induces cell adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer.
Sun L; Liu L; Liu X; Wang Y; Li M; Yao L; Yang J; Ji G; Guo C; Pan Y; Liang S; Wang B; Ding J; Zhang H; Shi Y
Cancer Sci; 2014 Jun; 105(6):651-9. PubMed ID: 24703465
[TBL] [Abstract][Full Text] [Related]
31. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
32. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Gu Y; Fei Z; Zhu R
Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
[TBL] [Abstract][Full Text] [Related]
33. Noncoding RNAs in gastric cancer: implications for drug resistance.
Wei L; Sun J; Zhang N; Zheng Y; Wang X; Lv L; Liu J; Xu Y; Shen Y; Yang M
Mol Cancer; 2020 Mar; 19(1):62. PubMed ID: 32192494
[TBL] [Abstract][Full Text] [Related]
34. Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer.
Riquelme I; Letelier P; Riffo-Campos AL; Brebi P; Roa JC
Int J Mol Sci; 2016 Mar; 17(3):424. PubMed ID: 27011182
[TBL] [Abstract][Full Text] [Related]
35. Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44(+)/Musashi-1(+) gastric cancer stem cells.
Xu M; Gong A; Yang H; George SK; Jiao Z; Huang H; Jiang X; Zhang Y
Cancer Lett; 2015 Dec; 369(1):124-33. PubMed ID: 26276718
[TBL] [Abstract][Full Text] [Related]
36. Progress and current status of molecule-targeted therapy and drug resistance in gastric cancer.
Chen Z; Li Y; Tan B; Zhao Q; Fan L; Li F; Zhao X
Drugs Today (Barc); 2020 Jul; 56(7):469-482. PubMed ID: 32648857
[TBL] [Abstract][Full Text] [Related]
37. The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.
Yu B; Gu D; Zhang X; Liu B; Xie J
J Genet Genomics; 2017 Aug; 44(8):375-383. PubMed ID: 28847472
[TBL] [Abstract][Full Text] [Related]
38. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
Heinrich MC; Corless CL
J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
[TBL] [Abstract][Full Text] [Related]
39. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.
Zhang D; Fan D
Future Oncol; 2010 Apr; 6(4):527-37. PubMed ID: 20373867
[TBL] [Abstract][Full Text] [Related]
40. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway.
Zhou J; Chen Q
FASEB J; 2019 Mar; 33(3):3420-3436. PubMed ID: 30576232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
